Protocol Ledger

NCT07112378 · Phase III · RECRUITING

A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis

Interventional Phase III clinical trial protocol NCT07112378 sponsored by Regeneron Pharmaceuticals in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-11-10 Enrollment: 20 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07112378
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)20 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07112378
Protocol FieldVerified Registry Value
NCT IdentifierNCT07112378
Consolidated Lead SponsorRegeneron Pharmaceuticals
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment20 participants (ESTIMATED)
Registered Start Date2025-11-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Regeneron Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI